Roche, Basel, Switzerland, and MySugr, Vienna, Austria, have signed an agreement under which Roche acquired all shares of MySugr GmbH. Counting more than one million users globally, MySugr provides mobile diabetes management platforms and seeks to become an integral part of Roche’s new patient-centered digital health services platform in diabetes care. The acquisition allows Roche to expand its position in the area of diabetes management.
Roland Diggelmann, Roche Diagnostics.
“We are excited about this agreement, as we will be able to offer seamlessly accessible patient solutions within an open platform to better respond to the unmet needs of people with diabetes,” says Roland Diggelmann, CEO of Roche Diagnostics. “Our aim is to support people with diabetes to spend more time in their ideal glucose target range and improve their quality of life. Having partnered with MySugr since 2014, we see an excellent cultural fit, as both our companies are passionate about taking diabetes management to the next level and making a difference in managing diabetes.”
“We started MySugr to solve our everyday problems and simplify diabetes therapy through smartphones,” says Frank Westermann, CEO and cofounder of mySugr. “The MySugr team has filled a gap for over a million loyal users so far, and with Roche’s diabetes expertise and global network, MySugr will become an indispensable companion for hassle-free life.”
As a focal point for Roche`s integrated diabetes management strategy, MySugr is anticipated to remain a separate legal entity with an open platform for all diabetes devices and services. Users will continue to have the ability to upload blood glucose data automatically from their preferred device into the MySugr logbook app, and will also benefit from facilitated data sharing with healthcare professionals and caregivers.
